NCT07144995Not yet recruiting
MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma
Adjusted Indirect Treatment Comparison of Fruquintinib-based Therapy Versus Standard Care in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A MAIC Analysis.
Source: ClinicalTrials.gov · Last updated 28 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric/GEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1143 (estimated)
- First submitted
- 5 Aug 2025
- Start date
- Sept 2025
- Primary completion date
- Aug 2026
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07144995
What you commit to
- Study type: Observational
- Planned participants: 1143
- From Sept 2025 to the primary completion date, Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior fruquintinib exposure (control arm only)
Other
- Missing key outcome data
- Incomplete baseline characteristics for \>2 matching variables
Who the study is looking for
- Histologically confirmed gastric/GEJ adenocarcinoma
- Advanced or metastatic disease
- ECOG 0-1
- Received either fruquintinib + paclitaxel or reference regimen
- Available baseline characteristics for matching variables
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Related publications
- Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.J Comp Eff Res · 2026 · PMID 42583940
This page is information, not medical advice. Discuss any trial with your doctor.